Heparin-induced thrombocytopenia testing is over-utilized in cirrhosis & correlates with poor clinical outcomes

Annals of Hepatology

Volumn 13, Issue 5, 2014, Pages 548-554

  Martin, Karlyn ^a   Kia, Leila ^a   Parikh, Neehar D ^b   Kulik, Laura ^a   McMahon, Brandon ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

HIT; Survival; Thrombosis; Transplantation

Indexed keywords

ARGATROBAN; FONDAPARINUX; HEPARIN PLATELET FACTOR 4 ANTIBODY; WARFARIN; ANTIBODY; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; HEPARIN;

ADULT; ANTIBODY DETECTION; ARTICLE; ASSAY; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EXPOSURE; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOASSAY; INCIDENCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PREDICTIVE VALUE; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEROTONIN RELEASE ASSAY; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT OUTCOME; AGED; BLOOD; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; KAPLAN MEIER METHOD; LABORATORY DIAGNOSIS; MIDDLE AGED; PROGNOSIS; THROMBOCYTOPENIA; TIME; UNITED STATES; UNNECESSARY PROCEDURE; UTILIZATION;

ADULT; AGED; ANTIBODIES; ANTICOAGULANTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHICAGO; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE REACTIONS; FEMALE; HEPARIN; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA; TIME FACTORS; UNNECESSARY PROCEDURES;

EID: 84906046778     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31255-4     Document Type: Article

References (19)

1. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106: 2710-5.
2. Hughes M, Hayward CP, Warkentin TE, Horsewood P, Chorneyko KA, Kelton JG. Morphological analysis of micro-particle generation in heparin-induced thrombocytopenia. Blood 2000; 96: 188-94.
3. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535-55.
4. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-7.
5. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 7S-47S.
6. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106: 629-35.
7. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-17.
8. Bechmann LP, Sichau M, Wichert M, Gerken G, Kroger K, Hilgard P. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011; 31: 75-82.
9. Davenport A. Optimization of heparin anticoagulation for hemodialysis. Hemodial Int 2011; 15(Suppl. 1): S43-S48.
10. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-56.
11. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759-65.
12. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012; 120: 4160-7.
13. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6: 1304-12.
14. Altuntas F, Matevosyan K, Burner J, Shen YM, Sarode R. Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia. Eur J Haematol 2008; 80: 429-35.
15. Fabris F, Luzzatto G, Soini B, Ramon R, Scandellari R, Randi ML, Girolami A. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med 2002; 252: 149-54.
16. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008; 53: 3012-7.
17. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010; 137: 1145-9.
18. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-60.
19. Fontana RJ. Prophylactic anticoagulation in cirrhotics: a paradox for prime time? Gastroenterology 2012; 143: 1138-41.